All In Biotech

Drug Trial Radar · NCT03175224

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

497

Planned (sponsor's estimate)

Start

Sep 27, 2017

Primary completion

Mar 30, 2026

Study completion Nov 30, 2026

Sponsor

Lead sponsor
Apollomics Inc.Industry
Sponsor type
Industry
First posted
Jun 5, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET * efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resistance with MET amplification and disease progression after documented CR or PR with 1st line EGFR inhibitors (EGFR-I)

Conditions

  • Solid Tumors
  • Advanced Cancer
  • Renal Cancer
  • Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma
  • NSCLC
  • Lung Cancer
  • Brain Tumor
  • Glioblastoma Multiforme
  • EGFR Gene Mutation
  • MET Amplification
  • HGF
  • Thyroid Cancer
  • Pancreatic Cancer
  • Colon Cancer
  • MET Alteration
  • MET Fusion
  • Exon 14 Skipping

Interventions

  • APL-101 Oral CapsulesDrug

    Subjects will receive APL-101 capsules BID for oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR = CR + PR) per IRC committee (BIRC) based on RECIST v1.1 (or relevant criteria per tumor type)Time frame: From time of informed consent signature through completion of treatment (1 cycle = 28 days) or progression

Locations

35 sites in 11 countries. Site status is shown where the registry gives one.

  • Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute

    Los Angeles, California · Recruiting

  • Moffitt

    Tampa, Florida · Active not recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Active not recruiting

  • University of North Carolina

    Chapel Hill, North Carolina · Recruiting

  • Penn State Milton S. Hershey Medical Center

    Hershey, Pennsylvania · Recruiting

  • University of Wisconsin

    Madison, Wisconsin · Recruiting

  • St Vincents Hospital Melbourne

    Melbourne, Australia · Recruiting

  • Cross Cancer Institute

    Edmonton, Canada · Recruiting

  • McGill University Health Center - Research Institute

    Montreal, Canada · Recruiting

  • Princess Margaret Hospital

    Toronto, Canada · Recruiting

  • Cancer Care Manitoba

    Winnipeg, Canada · Recruiting

  • CHRU de Brest - Hôpital Morvan

    Brest, France · Recruiting

  • Centre Leon Berard

    Lyon, France · Recruiting

  • Centre d'Essais Precoces en Cancerologie de Marseille

    Marseille, France · Recruiting

  • Hopital Bichat - Claude Bernard - AP-HP

    Paris, France · Recruiting

  • Gustave Roussy

    Villejuif, France · Recruiting

  • Orszagos Koranyi Pulmonologiai Intezet

    Budapest, Hungary · Recruiting

  • Komarom-Esztergom Varmegyei Szent Borbala Korhaz

    Tatabánya, Hungary · Recruiting

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola

    Bologna, Italy · Recruiting

  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

    Meldola, Italy · Recruiting

  • IRCCS Ospedale San Raffaele

    Milan, Italy · Recruiting

  • Istituto Europeo di Oncologia

    Milan, Italy · Recruiting

  • Istituto Oncologico Veneto-I.R.C.C.S. - Ospedale Busonera

    Padova, Italy · Recruiting

  • Private Medical Institution Euromedservice

    Saint Petersburg, Russia · Active not recruiting

  • National Cancer Centre Singapore

    Singapore, Singapore · Recruiting

  • Hospital Germans Trias i Pujol

    Badalona, Spain · Recruiting

  • Hospital Clinic Barcelona

    Barcelona, Spain · Recruiting

  • Hospital del Mar

    Barcelona, Spain · Recruiting

  • Institut Catala d'Oncologia - L'Hospitalet

    Barcelona, Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Recruiting

  • Instituto Valenciano de Oncologia

    Valencia, Spain · Recruiting

  • National Taiwan University Hospital

    Taipei, Taiwan · Recruiting

  • University College London Hospital

    London, United Kingdom · Recruiting

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom · Recruiting

  • Royal Marsden Hospital - Surrey

    Surrey Quays, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.